Welcome to our dedicated page for Geron SEC filings (Ticker: GERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Geron’s SEC disclosures is no small task. Clinical trial footnotes, preferred stock conversions, and imetelstat milestones sprawl across hundreds of pages. Investors searching “Geron quarterly earnings report 10-Q filing,” “Geron insider trading Form 4 transactions,” or simply “Geron SEC filings explained simply” often spend hours hunting for one number: cash runway. Our platform removes that friction.
Stock Titan’s AI-powered summaries pinpoint the R&D burn rate, partnership revenue, and trial progress buried in every document. Whether you need “Geron 8-K material events explained” after an unexpected efficacy update or a “Geron annual report 10-K simplified” before your valuation model, we translate technical jargon into plain English within seconds. Real-time alerts stream “Geron Form 4 insider transactions real-time,” flagging when executives adjust positions so you never miss a signal.
From proxy to prospectus, every filing type is covered:
- 10-K and 10-Q: drill into segment spending with “Geron earnings report filing analysis”.
- Form 4: monitor “Geron executive stock transactions Form 4” for buying or selling trends.
- DEF 14A: review “Geron proxy statement executive compensation” without spreadsheets.
- 8-K: catch material trial announcements the moment they hit EDGAR.
Use our expert insights to compare quarter-over-quarter R&D shifts, assess dilution risk from new equity offerings, and understand pipeline milestones—all without sifting through medical jargon. If you’ve ever searched “understanding Geron SEC documents with AI,” you’ve just found the answer.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin jointly report beneficial ownership of 43,000,000 shares of Geron Corp common stock, equal to 6.75% of the outstanding class. The filing shows the reporting persons hold shared voting and shared dispositive power and report no sole voting or dispositive power.
The ownership percentage is calculated using 636,917,758 shares outstanding per Geron's 10-Q; the filers certify the shares were not acquired to change or influence control and include a joint filing statement assigning responsibility for future amendments.
Harout Semerjian, President & CEO and a director of Geron Corp (GERN), received stock option grants on 08/07/2025 totaling 11,000,000 options exercisable into common stock at an exercise price of $1.30 per share and expiring on 08/06/2035. The awards are direct beneficial ownership and were reported on a Form 4.
The grants vest in two schedules: one award of 7,000,000 options vests with 875,000 shares on February 7, 2026 and the remaining 6,125,000 in 42 equal monthly installments beginning February 7, 2026; a second award of 4,000,000 options vests with 1,000,000 shares on August 7, 2026 and the remaining 3,000,000 in 36 equal monthly installments beginning August 7, 2026, provided the optionee continues to provide services to the Company. These details describe the size, price, expiry and service‑conditioned vesting of the executive option grants.
Event: Geron Corporation (GERN) filed an 8-K reporting the appointment of Harout Semerjian as President, Chief Executive Officer and director, effective August 7, 2025.
- CEO appointment: Mr. Semerjian replaces Dawn C. Bir and will fill a Class I board vacancy through the 2027 annual meeting.
- Compensation: Annual base salary $800,000; annual performance target bonus 70% of base salary (prorated for 2025).
- Equity inducement: Grant of stock options to purchase 11,000,000 shares under the 2018 Inducement Award Plan; exercise price = Nasdaq closing price on start/grant date.
- Vesting: 7,000,000 options: 12.5% at six months then monthly over 42 months; 4,000,000 options: 25% at one year then monthly over 36 months; full vest upon Change in Control.
- Severance: Covered Termination: prorated target bonus, lump-sum equal to 18 months base salary, COBRA for up to 18 months; vested options remain exercisable until earlier of two years post-termination or original expiration.
- Plan amendments: Amended and Restated Severance Plan effective August 1, 2025 adds a CEO payment equal to 150% of target bonus upon a qualifying Change of Control; 2018 Inducement Award Plan amended to add 11,000,000 shares for inducement grants.
- Exhibits: Employment Agreement (Exhibit 10.1), Amended Severance Plan (Exhibit 10.2), Amended 2018 Inducement Plan (Exhibit 10.3).
FAQ
What is the current stock price of Geron (GERN)?
What is the market cap of Geron (GERN)?
